Compare Automatic Data Processing Inc (ADP) vs State Street SPDR S&P Biotech ETF (XBI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Automatic Data Processing Inc vs State Street SPDR S&P Biotech ETF — how do they compare? Automatic Data Processing Inc trades at $242.03 (market cap $98.17B), while State Street SPDR S&P Biotech ETF trades at $161. The key difference: Automatic Data Processing Inc pays a 2.77% dividend while State Street SPDR S&P Biotech ETF pays none, and State Street SPDR S&P Biotech ETF is trading nearer its 52-week high, Automatic Data Processing Inc nearer its low. Which is the better fit depends on your goals.
| ADP | XBI | |
|---|---|---|
Market Cap | $98.17B | — |
Sector | Industrials | Broad Market / Factor |
52-Week High | $310.94 | $163.87 |
52-Week Low | $188.79 | $84.71 |
Enterprise Value | $99.24B | — |
Dividend Yield | 2.77% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADP trades at $245.60, up 1.37% on the day, near its 52-week high. The stock shows bullish technical signals with consistent earnings beats in recent quarters. Revenue grew to $20.56 billion in 2025, with a net income margin of 20.12%. Analyst sentiment is mixed, with a consensus hold rating but a technical outlook suggesting strength. The company maintains strong profitability metrics and recently announced a dividend payment.
Outlook remains stable with projected revenue growth to $21.6 billion in 2026. Risks include competitive pressures and economic sensitivity. Opportunities lie in AI integration and margin expansion. The stock offers value through dividends and steady performance, though valuation multiples are elevated relative to historical averages.
XBI trades at $160.81, up 0.22% for the day, with a bullish technical signal driven by moving averages but overbought RSI readings. The ETF has surged approximately 17% over the past month, fueled by biotech sector momentum, AI-driven drug discovery advancements, and robust M&A activity. Analyst consensus remains neutral with a single hold rating, while recent news highlights strong performance relative to broader healthcare ETFs.
Outlook: XBI offers exposure to biotech growth catalysts including M&A and innovation, but high volatility and overbought conditions pose near-term risks. Long-term potential hinges on sector stability and pipeline successes, though investors face elevated beta and regulatory uncertainties.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Automatic Data Processing Inc
ADP is a provider of payroll and human capital management solutions servicing the full scope of businesses from micro to global enterprises. ADP was established in 1949 and serves over 990,000 clients primarily in the United States. ADP's employer services segment offers payroll, HCM solutions, HR outsourcing, insurance and retirement services. The smaller but faster-growing PEO segment provides HR outsourcing solutions to small and midsize businesses through a co-employment model.
Read more on ADP →About State Street SPDR S&P Biotech ETF
XBI is an equal-weighted ETF that tracks the U.S. biotechnology segment. It provides diversified exposure to small, mid, and large-cap biotech firms involved in drug discovery and medical research, such as Moderna and Exact Sciences.
Read more on XBI →
